Sorcha Waters

Articles by Sorcha Waters

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

ByRadhika Appaya,Erika P. Hamilton, MD,Thomas Decker,Hope S. Rugo, MD,Maria Fernandez Abad,Kevin Kalinsky, MD, MS,Qiang Liu,Mariya Rozenblit, MD,Barbara Radecka,Seock-Ah Im,Frances Visco,Alejandro Perez,Yogesh Chattar,Murat Akdere,Vaidyanathan Ganapathy,Sorcha Waters,Joyce O’Shaughnessy, MD

June 27th 2025

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

BySherene Loi, MD, PhD,Erica Stringer-Reasor,Jean-Sebastien Frenel,Mattea Reinisch,Ruth M. O’Regan,Michelino De Laurentiis,Yeon Hee Park,Anne O’Dea,Yen-Shen Lu,Valeria Gonzalez,Melissa Gao,Sorcha Waters,Huilin Hu,Binghe Xu

June 24th 2025

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

Latest Updated Articles

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
June 24th 2025

Trending on CancerNetwork

Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC

Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma

Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026

FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer

FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC